Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel
– SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax Combination Therapies – – First Patient Enrolled Achieved CR and in Fifth Month of
- Enrollment ex-China Expected to be Completed in November 2023 –
Location Sciences Group PLC on Friday said it has made significant progress on its proposed acquisition of Sorted Holdings Ltd. In late June, London-based location data verification company Location...
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) traded down 8.2% on Thursday . The stock traded as low as $1.65 and last traded at $1.67. 132,185 shares changed hands during trading, a decline of 48% from the average session volume of 254,776 shares. The stock had previously closed at $1.82. Analyst Upgrades […]